TP53 and cancer: P53 mutations in CRC not only impair wild-type p53 function (loss-of-function) but also provide neo-morphic (gain-of-function) activities such as promoting cell proliferation, invasion, metastasis, and chemoresistance, thereby promoting cancer progression [5, 8].